IP Library Granted Patent US 9,956,385
Granted Patent B2
US 9,956,385 · App. 13/926,515 · Granted May 1, 2018

Post-processing of a medical device to control morphology and mechanical properties

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,956,385
App. No.
13/926,515
Granted
May 1, 2018
Kind
B2
Abstract

A method of forming a coated medical device is described in which a coating including a therapeutic agent dispersed in a polymer or oligomer matrix is applied to an outer surface of the medical device. The coating is then post-processed to selectively remove a substantial portion of the polymer or oligomer matrix from the coating. The post-processed coating is then sterilized.

Claims (29)

1. A method of forming a coated medical device comprising:

applying a coating to an outer surface of a medical device, the coating including a therapeutic agent dispersed in a matrix of a polymer or oligomer excipient;

post-processing the medical device by immersion in a solvent or solution, thereby selectively removing a substantial portion of the polymer or oligomer excipient from the matrix in which the therapeutic agent is dispersed; and

sterilizing the post-processed medical device,

wherein the coating comprises less than 50% by weight of the therapeutic agent prior to post-processing, and the coating comprises greater than 50% by weight of the therapeutic agent after post-processing.

2. The method of claim 1 , wherein the therapeutic agent is substantially water insoluble.

3. The method of claim 2 , wherein the coating comprises 35% or less by weight of the therapeutic agent prior to post-processing, and the coating comprises 65% or more by weight of the therapeutic agent after post-processing.

4. The method of claim 2 , wherein less than 10% by weight of the therapeutic agent is removed from the coating during post-processing.

5. The method of claim 4 , wherein greater than 75% by weight of the polymer or oligomer excipient is removed from the coating during post-processing.

6. The method of claim 2 , wherein less than 15% by weight of therapeutic agent is removed from the coating during post-processing.

7. The method of claim 6 , wherein greater than 90% of the polymer or oligomer excipient is removed from the coating during post-processing.

8. The method of claim 2 , wherein the substantially water insoluble therapeutic agent comprises a taxane.

9. The method of claim 8 , wherein the taxane is selected from the group consisting of pactlitaxel, paclitaxel analogues, and paclitaxel derivatives thereof.

10. The method of claim 1 , wherein applying the coating comprises dip coating an expandable portion of the medical device in a solution comprising:

paclitaxel;

iodine;

a polymer; and

solvent.

11. The method of claim 10 , wherein the polymer is soluble in both water, and a solvent solution comprising an organic solvent and less than 20% by weight water.

12. The method of claim 10 , wherein the polymer has a molecular weight below 20,000 Daltons.

13. The method of claim 12 , wherein the polymer is polyethylene glycol (PEG).

14. The method of claim 13 , wherein the solvent comprises a mixture of ethanol and acetonitrile.

15. The method of claim 2 , wherein post-processing the medical device comprises immersing the medical device in an aqueous solution.

16. The method of claim 15 , wherein immersing the medical device in the aqueous solution comprises immersing the medical device in the aqueous solution for 5 minutes or less.

17. The method of claim 15 , wherein immersing the medical device in the aqueous solution comprises immersing the medical device in the aqueous solution for 1 minute or less.

18. The method of claim 2 , wherein post-processing the medical device comprises immersing the medical device in a solution comprising an organic solvent.

19. The method of claim 18 , wherein the solution further comprises water.

20. The method of claim 2 , wherein sterilizing the post-processed medical device comprises exposing the medical device to a relative humidity.

21. The method of claim 20 , wherein sterilizing comprises a pre-conditioning stage, a sterilization stage, and an aeration stage.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0142 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0066 →
SECURITY INTEREST (TERM) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0506 →
SECURITY INTEREST (REVOLVER) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0425 →
SECURITY INTEREST Recorded Jul 2, 2015
From: THE SPECTRANETICS CORPORATION
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 036055/0156 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2015
From: COVIDIEN LP
To: THE SPECTRANETICS CORPORATION
Reel/Frame 035074/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2013
From: RUANE, PATRICK H.
To: COVIDIEN LP
Reel/Frame 030955/0989 →